Table 3

Multivariate analysis of risk factors associated with new vertebral fractures
Variable Total AS patients AS patients without baseline VFs
(nā€‰=ā€‰298) (nā€‰=ā€‰268)
Odds ratio 95% CI P-value Odds ratio 95% CI P-value
TNF inhibitor
Baseline VF 12.8 3.6 to 45.3 <0.001
HLA-B27
Uveitis
SASSS progression
CRP increase 5.4 1.7 to 17.7 0.005 4.8 1.4 to 15.9 0.011

AS, ankylosing spondylitis; TNF, tumor necrosis factor; SASSS, Stokes ankylosing spondylitis spine score; CRP, C-reactive protein.

Kang et al.

Kang et al. Arthritis Research & Therapy 2014 16:R124   doi:10.1186/ar4581

Open Data